Data investigation
Tirzepatide in Ten- to Seventeen-Year-Olds
Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.
Youth-onset type 2 diabetes is not adult diabetes in a smaller body. It moves faster, responds worse to the medicines that work in adults, and has very few approved treatments. In a trial of 99 people aged 10 to 17, tirzepatide lowered HbA1c by 2.23%, while the placebo group’s blood sugar went up.[1]
Why the placebo column matters most
In most diabetes trials the control group holds roughly steady. Here it deteriorated. An HbA1c rise of 0.05% over 30 weeks is small in absolute terms, but it is in the wrong direction, in children whose diabetes was already inadequately controlled on metformin, basal insulin, or both. That is what an aggressive disease looks like in a control group.
In the placebo group, HbA1c rose 0.05% over 30 weeks.
That deterioration is also part of why the treatment effect here is so large. The estimated difference between groups was 2.28 percentage points (95% CI −2.87 to −1.69). Some of that gap is the drug working, and some is the comparison arm losing ground.
What was measured
Across 39 sites in eight countries, participants aged 10 to under 18 with youth-onset type 2 diabetes were randomized in equal thirds to tirzepatide 5 mg, tirzepatide 10 mg, or placebo, for 30 weeks double-blind. Everyone then received tirzepatide for a further 22 weeks. Average age was 14.7, average starting HbA1c 8.04%, and 61% were girls.
| Outcome | Tirzepatide | Placebo |
|---|---|---|
| HbA1c change (pooled doses) | −2.23% | +0.05% |
| BMI change, 5 mg | −7.4% | −0.4% |
| BMI change, 10 mg | −11.2% | −0.4% |
| Stopped for an adverse event | 2 of 32 (6%) on 5 mg | — |
Gastrointestinal effects were the most common adverse events. All were mild to moderate, and they became less frequent over time. No deaths occurred. The authors describe the safety profile as consistent with what has been seen in adults.
What 99 children cannot tell you
The 52-week durability claim needs the same care. The double-blind comparison ran 30 weeks; after that everyone received tirzepatide. So “sustained to 52 weeks” describes people continuing to do well on a drug, with no control group left to compare them against.
- Growth and puberty are not addressed by 30 weeks of data.
- Bone accrual, which happens largely in adolescence, is not measured.
- What happens on stopping is unstudied in this age group, and nobody plans to medicate a ten-year-old indefinitely without knowing.
- The trial was funded by Eli Lilly, which makes tirzepatide.
Where this sits among the pediatric evidence
Three separate questions get conflated in coverage of these drugs in young people, and they have different evidence behind them.
| Question | Where we cover it |
|---|---|
| Weight in adolescents with obesity | GLP-1 drugs in teenagers |
| Metabolic markers in those same adolescents | what changed in the teenagers’ bloodwork |
| Blood sugar in youth-onset type 2 diabetes | This page |
The distinction matters because the third has something the first two do not: a direct measure of a condition that is actively damaging the child while the trial runs. In diabetes, HbA1c measures the disease itself; it is also the standard surrogate for complications that take decades to appear. That makes this the strongest pediatric case in the class, though it is still 99 children over 30 weeks.
Frequently Asked Questions
References
- 1.Hannon TS, Chao LC, Barrientos-Pérez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet. 2025. PMID: 40975112.
Compare the sellers
Related research
The Old Cheap Drug Keeps Winning
A network meta-analysis of 41 pediatric trials found semaglutide producing the largest BMI reduction, and concluded an older, cheaper combination may be the better option.
7 min read
What Changed in the Teenagers' Bloodwork
A STEP TEENS analysis found insulin resistance down 35%, liver enzymes down 18%, and lipids improved in 12-to-17-year-olds. All of it is bloodwork, and the outcomes it stands in for are decades away.
7 min read
GLP-1 Drugs in Teenagers: What 18 Trials Show
Eighteen randomized trials in 1,402 children and adolescents with obesity, prediabetes or type 2 diabetes found improvements across every metabolic measure. Weight fell 3.02 kg more than on placebo, and the median treatment duration across all of them was half a year.
6 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
An Oral Pill in a Diabetes Population
Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.
7 min read
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
7 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Direct Meds
From $299/mo
Get started →HealthRX
From $214/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $179/mo, prepaid
Get started →